Angiotensin II and coronary artery disease, congestive heart failure, and sudden cardiac death

Basic Research in Cardiology

Volumn 93, Issue 2 SUPPL., 1998, Pages 101-108

  Dietz, R ^a   Von Harsdorf, R ^a   Gross, M ^a   Kramer J ^a   Gulba, D ^a   Willenbrock, R ^a   Osterziel, K J ^a  

^a Franz Volhard Klinik   (Germany)

Author keywords

Angiotensin II; Congestive heart failure; Coronary artery disease; Sudden cardiac death

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; GROWTH FACTOR; GROWTH HORMONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LOSARTAN; NISOLDIPINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PROBUCOL; RAMIPRIL; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; TRAPIDIL; VASODILATOR AGENT;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE; CORONARY ARTERY DISEASE; COUGHING; DRUG EFFICACY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPOTENSION; MUSCLE HYPERTROPHY; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; SUDDEN DEATH; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

ANGIOTENSIN II; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, CARDIOVASCULAR;

EID: 0031737514     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-82
2. The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435
3. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691
4. [published erratum appears in N Engl J Med 1992 Dec 10; 327(24): 1768]
5. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-3
6. Abe J, Deguchi J, Matsumoto T, Takuwa N, Noda M, Ohno M, Makuuchi M, Kurokawa K, Takuwa Y (1997) Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: A link between angiotensin II and intimal thickening. Circulation 96: 1906-1913 (Pubitemid 27400752)
7. Assoian RK, Marcantonio EE (1996) The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest 98: 2436-2439 (Pubitemid 26415061)
8. Ball SG (1992) Cardioprotection and ACE inhibitors. Clin Physiol Biochem 9: 98-104
9. Blaufarb IS, Sonnenblick EH (1996) The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 77: 8C-16C
10. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. (1991) Acomparison of enalapril with hydralazineisosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310
11. Dietz R, Osterziel KJ (1996) New aspects of ACE inhibitor treatment of heart failure. Z Kardiol 6: 241-246 (Pubitemid 26419598)
12. Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450- 1456
13. [published erratum appears in JAMA 1995 Aug 9; 274 (6): 462]
14. Harada K, Komuro I, Hayashi D, Sugaya T, Murakami K, Yazaki Y (1998) Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 97: 315-3 (Pubitemid 28074330)
15. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y, Nakao K (1997) Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: Evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96: 3737- 3744 (Pubitemid 27513456)
16. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H (1995) Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259
17. Lamas GA, Pfeffer MA (1991) Left ventricular remodeling after acute myocardial infarction: Clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am Heart J 121: 1194-1202
18. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G (1995) ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 92: 3132-3137
19. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG (1997) Role of superoxide in angiotensin II-induced but not catecholamine- induced hypertension. Circulation 95: 588-593 (Pubitemid 27063033)
20. Li PF, Dietz R, von Harsdorf R (1997) Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96: 3602-3609 (Pubitemid 27513439)
21. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S (1996) Survival after myocardial infarction in rats: Captopril versus losartan. J Am Coll Cardiol 27: 714-719 (Pubitemid 26080396)
22. Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker AE, Hiwada K, Kamitani A, Kamide K, Higaki J, Ogihara T (1997) Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 96: 3328-3337 (Pubitemid 27513402)
23. Oskarsson HJ, Heistad DD (1997) Oxidative stress produced by angiotensin too. Implications for hypertension and vascular injury. Circulation 95: 557-559 (Pubitemid 27063025)
24. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock R, Anker SA, Poole-Wilson PA, Ranke M, Dietz R (1998) Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351: 1233-1237 (Pubitemid 28181962)
25. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677
26. Pham D, Laporte S, Perodin J, Bourgeois R, Escher E (1996) What can angiotensin antagonists do that converting-enzyme inhibition can't: The case of post-angioplastic restenosis. Can J Physiol Pharmacol 74: 867-877 (Pubitemid 26426577)
27. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752 (Pubitemid 27122456)
28. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/ NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923
29. Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P (1998) Experimental evidence to support ELITE. Lancet 351: 644-645 (Pubitemid 28098451)
30. Sharpe N (1993) The effects of ACE inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol 22: S9-12
31. Sirois MG, Simons M, Edelman ER (1997) Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening. Circulation 95: 669-676 (Pubitemid 27063045)
32. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P (1997) Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 337: 365-372 (Pubitemid 27328366)
33. Thienelt CD, Weinberg EO, Bartunek J, Lorell BH (1997) Load-induced growth responses in isolated adult rat hearts. Role of the AT1 receptor. Circulation 95: 2677- 2683 (Pubitemid 27255497)
34. Wong J, Rauhoft C, Dilley RJ, Agrotis A, Jennings GL, Bobik A(1997) Angiotensinconverting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation 96: 1631- 1640 (Pubitemid 27375363)
35. Yamazaki T, Yazaki Y(1997) Is there major involvement of the renin-angiotensin system in cardiac hypertrophy? Circ Res 81: 639-642 (Pubitemid 27467196)
36. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Ohshima S, Nishiyama S, Seki A, Kato K, Nishimura S, Kanoh T, Yamaguchi H (1997) Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 30: 855-862 (Pubitemid 27435873)